JP2020510011A5 - - Google Patents

Info

Publication number

JP2020510011A5

JP2020510011A5 JP2019548370A JP2019548370A JP2020510011A5 JP 2020510011 A5 JP2020510011 A5 JP 2020510011A5 JP 2019548370 A JP2019548370 A JP 2019548370A JP 2019548370 A JP2019548370 A JP 2019548370A JP 2020510011 A5 JP2020510011 A5 JP 2020510011A5

Authority

JP

Japan

Prior art keywords

glucocorticoid receptor

patient

composition

composition according

administered

Prior art date

2018-03-08

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 229940117965 Glucocorticoid receptor modulator Drugs 0.000 claims description 37
• 208000014311 Cushing syndrome Diseases 0.000 claims description 20
• 150000003943 catecholamines Chemical class 0.000 claims description 20
• 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 20
• 102000003676 Glucocorticoid Receptors Human genes 0.000 claims description 16
• 108090000079 Glucocorticoid Receptors Proteins 0.000 claims description 16
• 229940126013 glucocorticoid receptor antagonist Drugs 0.000 claims description 16
• 239000003850 glucocorticoid receptor antagonist Substances 0.000 claims description 16
• 230000003248 secreting effect Effects 0.000 claims description 15
• VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical group C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 claims description 12
• 229960003248 mifepristone Drugs 0.000 claims description 12
• JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 claims description 10
• 229940124750 glucocorticoid receptor agonist Drugs 0.000 claims description 10
• 206010028980 Neoplasm Diseases 0.000 claims description 8
• 201000011519 neuroendocrine tumor Diseases 0.000 claims description 8
• 206010052399 Neuroendocrine tumour Diseases 0.000 claims description 5
• 208000016065 neuroendocrine neoplasm Diseases 0.000 claims description 5
• 102000004305 alpha Adrenergic Receptors Human genes 0.000 claims description 4
• 108090000861 alpha Adrenergic Receptors Proteins 0.000 claims description 4
• 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 4
• 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 4
• 238000002512 chemotherapy Methods 0.000 claims description 4
• 239000003087 receptor blocking agent Substances 0.000 claims description 4
• 239000003862 glucocorticoid Substances 0.000 claims description 3
• 229940075993 receptor modulator Drugs 0.000 claims description 3
• NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 3
• 230000028327 secretion Effects 0.000 claims 1
• 238000000034 method Methods 0.000 description 39
• 239000003470 adrenal cortex hormone Substances 0.000 description 2
• RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 2
• 229940044551 receptor antagonist Drugs 0.000 description 2
• 239000002464 receptor antagonist Substances 0.000 description 2